Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa
- Conditions
- Interventions
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 7
- Registration Number
- NCT00478244
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2007-05-17
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 63
- Registration Number
- NCT00475020
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 233
- Registration Number
- NCT00469144
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 72
- Registration Number
- NCT00469014
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H
- Conditions
- First Posted Date
- 2007-04-10
- Last Posted Date
- 2008-11-18
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 10
- Registration Number
- NCT00458250
- Locations
- 🇮🇷
Hematology-Oncology & BMT Research Center, Tehran, Iran, Islamic Republic of
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
- Conditions
- First Posted Date
- 2007-03-30
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- The University of New South Wales
- Target Recruit Count
- 2000
- Registration Number
- NCT00454480
- Locations
- 🇬🇧
Queen's Hospital, Burton-upon-Trent, England, United Kingdom
🇬🇧Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom
🇬🇧Hereford Hospitals, Hereford, United Kingdom
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
- Conditions
- Interventions
- Biological: sargramostimBiological: anti-thymocyte globulinBiological: therapeutic allogeneic lymphocytesDrug: busulfanDrug: fludarabine phosphateDrug: methotrexateDrug: tacrolimusProcedure: nonmyeloablative allogeneic hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2007-03-16
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 71
- Registration Number
- NCT00448201
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen
- Conditions
- Interventions
- First Posted Date
- 2007-03-16
- Last Posted Date
- 2017-07-17
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT00448357
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00446173
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
- Conditions
- Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Childhood Acute Myeloid Leukemia in RemissionChildhood Myelodysplastic Syndromesde Novo Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2007-03-09
- Last Posted Date
- 2018-01-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT00445744
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.